• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Is Now The Time To Invest In Cannabis Stocks? Trends And Long-Term Predictions From Industry Experts

    7/5/24 9:55:08 AM ET
    $CGC
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email

    The recent federal court ruling dismissing a lawsuit from major cannabis companies that sought to prevent the U.S. government from enforcing prohibition against their in-state activities, could signal critical implications for cannabis stocks and the broader industry.

    On a recent episode of the The Dales Report Trade to Black podcast, Dan Ahrens, manager of AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (NYSE:MSOS), shared insights into the consequences of the ruling, which the market appears to have interpreted negatively. However, according to Ahrens, this legal maneuver is part of a strategic approach to bring the issue to the Supreme Court, potentially leading to favorable regulatory changes.

    Legal Developments: Impact On Cannabis Stocks

    The stock market has shown volatility in response to these developments, largely due to the broader regulatory landscape and investor sentiment. Ahrens highlighted that U.S. cannabis stocks are highly sensitive to regulatory news, leading to significant market fluctuations and underscoring the industry’s dependency on favorable legal and regulatory outcomes.

    Furthermore, this sensitivity is compounded by investor concerns over the slow progress in cannabis policy reform, which has kept many companies like Trulieve Cannabis (OTC:TCNNF), Canopy Growth (NASDAQ:CGC) and Tilray Brands (NASDAQ:TLRY) operating in the red, as noted by The Motley Fool.

    Read Also: Executive Changes In Cannabis Industry You Should Know About, New Appointments & More

    Cannabis Sector Growth And Long-Term Expectations

    As the industry navigates through these regulatory developments, Boris Jordan, executive chairman of Curaleaf Holdings (OTC:CURLF), predicts a drastic consolidation in the industry over the next decade, driven by unsustainable current operations amid federal restrictions. “In the U.S., we definitely need consolidation because the cost structure is completely out of whack,” stated Jordan, according to The Motley Fool. He anticipates that only five to ten major players will dominate the market within the next decade due to these pressures.

    Both Jordan and Ahrens agree on the significant growth potential within the sector, propelled by eventual regulatory changes and increasing market acceptance. Ahrens is optimistic about the industry’s trajectory, suggesting a beneficial reevaluation of cannabis policy. Similarly, Jordan's projections indicate a maturing market, potentially yielding a more stable and profitable environment for the leading companies.

    High Risk, High Reward For Cannabis Investors

    In line with these expert analyses, the impending rescheduling of cannabis and potential legislative changes, such as the SAFE Banking Act, promise to lighten regulatory burdens. Javier Hasse of Benzinga highlights that these developments could spur significant growth and investment opportunities, underscoring a robust long-term potential for the market, especially for multi-state operators that are well-positioned to capitalize on these changes.

    Read Next:

    • EXCLUSIVE: Can Data Fix Cannabis Banking? Green Check CEO Breaks Down The Solution

    Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC
    $TLRY

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    4/3/2026$10.00Neutral → Buy
    Roth Capital
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    Tilray Brands Inc.
    $TLRY
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    Canopy Growth Corporation
    $CGC
    4/4/2023Underperform → Mkt Perform
    Bernstein
    Tilray Brands Inc.
    $TLRY
    11/2/2022$3.90Mkt Perform
    Bernstein
    More analyst ratings

    $CGC
    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/3/26 10:44:58 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/2/26 7:55:13 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    SEC Filings

    View All

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    4/1/26 4:30:43 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    4/1/26 7:00:14 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    3/16/26 7:59:07 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yanofsky Theresa

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:22 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Atkins M Shan

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:02 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Bayern Joseph

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:15:39 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Expands Canadian Cannabis Portfolio with Launch of PORTAL™, A New High Intensity Brand for the Experienced Consumer

    TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. company (NASDAQ:TLRY, TSX:TLRY) a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the launch of PORTAL™, its newest cannabis brand engineered specifically for seasoned, high‑tolerance consumers seeking uncompromising potency, consistency, and performance, just ahead of 4/20 next month. The vape and infused pre-roll categories have grown rapidly, but with that growth has come sameness. Similar products. Familiar promises. Diminishing returns for consumers who know exactly what they're looking for and rarely find it. PORTAL was created to c

    4/8/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Distillery Introduces Honey Whiskey Crafted with Rare Nigerian Goldswarm Honey—A Must-Try for Whiskey Enthusiasts

    BRECKENRIDGE, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), announces the re-launch of Breckenridge Honey Whiskey, a bold new expression infused with Goldswarm Raw Honey from Nigeria. Bottled at 36% ABV (72 proof), the whiskey delivers a rich, smooth, golden finish that is both unmistakable and deeply flavorful. Photo credit: Breckenridge Distillery Originally launched in 2025 in partnership with the Denver Broncos, Breckenridge Honey Whiskey now stands proudly within the Breckenridge Whiskey portfolio. The expression reflects the distillery's commitment to crafting ap

    4/7/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year

    International Cannabis Accelerates with 73% Net Revenue Growth and 100% Increase in Cannabis Flower Sales Volume Year-Over-Year Canadian Adult-Use and Medical Cannabis Net Revenue Combined Increased 8% Year-Over-Year; Tilray Maintains #1 Cannabis Leadership Position in Canada by Revenue BrewDog Acquisition1 for ~£40 Million Cash Positions Tilray as a Global Craft Beverage Leader with Multi-Region Expansion Across Europe, Middle East, Australia, Asia-Pacific and the U.S. Strong Balance Sheet Supports Growth with $265 Million in Cash and Marketable Securities2 and ~$3.5 Million Net Cash NEW YORK and LONDON and LEAMINGTON, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("

    4/1/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

    NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Ti

    3/25/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region

    Acquisition Includes BrewDog's Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia's National Retail and Grocery Channels and Introduce Broader Beverage Portfolio Across Asia-Pacific NEW YORK and BRISBANE, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the completion of the acquisition of BrewDog Brewing Australia Pty Ltd., including BrewDog's Australian brewing and pr

    3/9/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care